Credit Suisse lowered the firm’s price target on AMN Healthcare to $105 from $115 and keeps an Outperform rating on the shares. AMN’s Q2 results were slightly better than estimates, though the company reduced its revenue and EBITDA outlook for Q3, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on AMN: